Shohei Koide
Professor New York University Grossman School of Medicine
Seminars
Thursday 18th September 2025
Panel Discussion: Delving into Strategies to Achieve Selective Targeting of NRAS & HRAS Mutations for Successfully Treating a Wide Array of Cancers
2:30 pm
- What preclinical evidence is there which showcases the potential for NRAS-targeting programs?
- How to selectively target NRAS and minimize off-target effects?
- How to develop a successful patient stratification strategy and clinical trial design for RAS-mutant cancer programs?
Thursday 18th September 2025
Leveraging Strategies for Selective Targeting of NRAS & Q61 Mutations for Cancer Treatment
2:00 pm
- Synthetic binding proteins are powerful tools for examining the feasibility of achieving unprecedented specificity and discovering new druggable sites
- We have developed monobodies, synthetic binding proteins, that show pan-NRAS and Q61Xselective specificity profiles, and defined their structural bases
- A new protein delivery technology enables efficient and selective inhibition of RAS signaling with monobodies, expanding their utility as tool biologics and potential therapeutics
